Global pharma major Lupin Limited (Lupin) announced the launch of the United States Food and Drug Administration (FDA) approved Minzoya (levonorgestrel and ethinyl estradiol tablets, USP and ferrous bisglycinate tablets), 0.1 mg/0.02 mg and 36.5 mg. Minzoya (levonorgestrel and ethinyl estradiol tablets, USP and ferrous bisglycinate tablets) 0.1 mg/0.02 mg and 36.5 mg is a generic equivalent of Balcoltra (levonorgestrel and ethinyl estradiol tablets, USP and ferrous bisglycinate tablets) 0.1 mg/0.02 mg and 36.5 mg, of Avion Pharmaceuticals LLC., indicated for use by females of reproductive potential to prevent pregnancy. Levonorgestrel and ethinyl estradiol tablets, USP and ferrous bisglycinate tablets (Balcoltra) had an estimated annual sale of USD 24 million in the US (IQVIA MAT November 2024).
|